Antibody discovery collaboration – Immunai and Boehringer Ingelheim expand T-cell target search

Immunai signed a research collaboration with Boehringer Ingelheim valued at up to $15 million to identify T-cell dysfunction patterns for oncology and autoimmune target discovery. The multi-year partnership runs through 2027, with phases focused on collecting thousands of patient samples and applying Immunai’s single-cell immune profiling platform. The work integrates multiomic modalities including single-cell RNA-seq, CITE-seq, proteomics and spatial transcriptomics, then uses AI-based immune system models to generate target hypotheses for Boehringer Ingelheim’s discovery pipeline. The collaboration follows Immunai’s previously disclosed expanded partnership with AstraZeneca. For biotech industry observers, the deal signals continued pharma demand for clinically grounded immune atlas data and functional target nomination platforms rather than purely observational biomarker strategies.